2024-04-09

-- Poster presentations to highlight application of company’s innovative CHAMPÒ technology to important cancer targets including KRAS

BOSTON, MA and HANGZHOU, China, April 4, 2024 -- Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting being held in San Diego, CA USA, 5-10 April 2024. The poster will describe the mechanism of action for Ranok’s tumor-targeted, Chaperone-mediated Protein Degradation CHAMPÒ technology. Ranok’s most advanced CHAMP program, RNK05047, which targets the bromodomain protein BRD4, is currently in Phase 1 clinical trials in the USA and China.

Details for the poster presentation are as follows:

Abstract: 6053

Title: Mechanism of action of tumor-selective, chaperone-mediated protein degraders (CHAMPs)

Date and time: Tuesday, 9 April 2024 at 1:30-5:00 PM PDT

Presenter: Xiangcai Yang, Ph.D., Associate Director of Biology, Ranok Therapeutics

Session category: Experimental and Molecular Therapeutics

Session title: Targeted Protein Degraders (PO.ET09.10)

Location: Poster section 30

Poster board number: 12

A second poster presentation from the laboratory of Ranok’s collaborator, Dr. Takeshi Shimamura of the University of Illinois Chicago, Chicago, Illinois, USA will discuss the application of CHAMP technology to treat resistance to KRAS(G12D) inhibitors in cancer:

Abstract: 1932

Title: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90

hetero-bifunctional small molecule therapeutic agent

Date and time: Monday, 8 April 2024 at 9:00 AM-12:30 PM PDT

Presenter: Ines Pulido Endrino, Ph.D., University of Illinois Chicago

Session category: Experimental and Molecular Therapeutics

Session title: Drug Resistance 2: Ras GTPase (PO.ET03.04)

Location: Poster section 24

Poster board number: 10

About Ranok’s CHAMPâ platform

Ranok’s proprietary Chaperone-mediated Protein Degradation (CHAMPâ) platform takes advantage of the cellular chaperone network, which regulates the folding and stability of proteins, distinguishing it from other targeted protein degradation approaches. CHAMPs have a number of unique advantages, such as the evasion of mechanisms of drug resistance, and are designed to improve safety and efficacy due to the selective targeting of disease tissues.

About RNK05047

RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMPâ. The bromodomain transcription factor BRD4 is a key epigenetic regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. Phase 1 trials of RNK05047 are currently underway in both the U.S. and China to assess its safety, tolerability and pharmacokinetics, and also include measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints. Initial results are expected in the second half of 2024.

About Ranok Therapeutics

Ranok is a privately held biopharmaceutical company that is pioneering CHAMPâ, an innovative approach to targeted protein degradation for the discovery and development of novel therapeutics. Our R&D team brings deep biological insight and chemistry expertise to rapidly identify and advance CHAMP degraders for a variety of important disease targets, with the goal to create transformative medicines that benefit patients around the world suffering from cancer and other serious diseases. For more information, please visit the company website at www.ranoktherapeutics.com or follow us on Twitter (@RanokTx) and LinkedIn.